Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MOXR0916 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MOXR0916: Dose Escalation Stage | EXPERIMENTAL | Participants in different cohorts (according to MOXR0916 dose received) will receive escalating doses of MOXR0916 to determine the MTD or maximum administered dose (MAD) for 21 to 42 days. |
| MOXR0916: Expansion Stage | EXPERIMENTAL | Participants in different cohorts (according to different cancer types, prior therapy and mandatory procedures on study) will receive MOXR0916 at the highest dose level that has already been deemed to be tolerable in the dose escalation stage until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (approximately up to 3 years). |
| Name | Type | Description |
|---|---|---|
| MOXR0916 | DRUG | MOXR0916 will be administered as intravenous infusion on Day 1 of each 21-day cycle. |
Inclusion Criteria: * Histologic documentation of locally advanced, recurrent or metastatic incurable solid malignancy that has progressed after all available standard therapy or for which standard therapy has proven to be ineffective or intolerable, or is considered inappropriate * Confirmed avail...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
MOXR0916 is an investigational small molecule being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is being developed by Roche Holding AG for use in oncology, specifically targeting patients with locally advanced or metastatic solid tumors.
MOXR0916 is being developed by Roche Holding AG, a multinational healthcare company. The company's stock is traded under the ticker symbol RHHBY. Roche is conducting clinical research to evaluate the safety and pharmacokinetics of MOXR0916 in patients with advanced solid tumors.
MOXR0916 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study has been completed to assess its safety and pharmacokinetics in participants with locally advanced or metastatic solid tumors.
MOXR0916 has one completed clinical trial, identified as NCT02219724. This Phase 1 study assessed the safety and pharmacokinetics of MOXR0916 in participants with locally advanced or metastatic solid tumors. The trial enrolled 174 participants and was conducted in the United States, Australia, Belgium, Canada, South Korea, and Spain.
MOXR0916 is a small molecule therapeutic agent. Its specific molecular target has not been disclosed in available information. The drug is being investigated for its potential to treat neoplasms, including solid tumors, though its exact mechanism of action remains under study in clinical trials.
MOXR0916 is not FDA approved. It is an investigational drug currently in clinical development. The completed Phase 1 trial focused on safety and pharmacokinetics, and further studies would be needed to establish efficacy and safety before any regulatory approval could be considered.